Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMAT: L-Arginine and VEGF Angiogenesis in Coronary Artery Disease
NCT00134433Phase 2Completed
- Sponsor
- University of Ottawa Heart Institute
- Start
- Nov 2004
- Primary completion
- Mar 2007
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of arginine, VEGF165 plasmid DNA in coronary artery disease (CAD), sponsored by University of Ottawa Heart Institute. Started Nov 2004; status: completed.
02
Drugs
arginineVEGF165 plasmid DNA
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00134433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134433.